CHANGMAO BIO AGM: 100% Shareholder Support Secures 2026 Mandates, Audited 2025 Results Approved

Bulletin Express
05/28

Changmao Biochemical Engineering Company Limited (CHANGMAO BIO) reported full shareholder backing for all matters tabled at its Annual General Meeting (AGM) held on 28 May 2026 in Hong Kong.

• Participation and Voting Out of 529.70 million shares outstanding, 271.00 million shares—approximately 51.16% of issued capital—were voted in person or by proxy. Every resolution received 100% “For” votes, with no votes cast against or abstentions recorded.

• Ordinary Resolutions Passed 1. Approval of the audited consolidated financial statements and accompanying reports for the year ended 31 December 2025. 2. Re-appointment of PricewaterhouseCoopers as international auditor until the next AGM, with the Board authorised to determine remuneration. 3. Re-appointment of PricewaterhouseCoopers Zhong Tian LLP as domestic auditor on the same terms.

• Special Resolutions Passed 1. Authorisation granting the Board a general mandate to allot and issue new shares. 2. Adoption of amended Articles of Association following regulatory approval, with the Board empowered to execute related documentation.

• Independent Scrutiny Cheng & Cheng Limited, Certified Public Accountants, acted as scrutineer, verifying poll results against voting papers provided by the company.

The unanimous outcomes provide CHANGMAO BIO’s Board with renewed auditing arrangements, an enlarged capital issuance mandate, and updated corporate governance documentation for the forthcoming year.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10